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Background: Although prophylactic vaccines have been developed against HPV6, HPV11, HPV16 and HPV18 there is
the clear unmet medical need in order to justify the development of drugs targeting human papillomavirus replication.
The native host cells of HPVs are human primary keratinocytes which can be cultivated in raft cultures. However, this
method is difficult to use in high-throughput screening assays and the need for a cost-effective cellular system for
screening potential anti-HPV drug candidates during all stages of HPV genome replication remains.
Methods: U2OS cells were transfected with HPV11 wt or E8- minicircle genomes and their gene expression was
studied via 3′ RACE, 5′ RACE or via real time PCR methods. The DNA replication of these genomes was detected
by Southern blot methods.
Results: The analysis of HPV11 transcripts in U2OS cells showed that the patterns of promoter use, splice sites
and polyadenylation cleavage sites are identical to those previously characterized in human HPV-related lesions,
human squamous carcinoma cell lines (e.g., SSC-4) and laryngeal papillomas. Transcriptional initiation from the
three previously described HPV11 promoters in the E6 and E7 ORFs (P90, P264, and P674-714) were functional,
and these promoters were used together with two promoter regions in the E1 ORF (P1092 and P1372). Mutating
the E8 ORF ATG start codon to ACG eliminated the translation of fusion proteins from the E8 ORF coupled to E1
and E2 proteins C-terminal sequences, leading to the de-repression of gene expression (particularly from the
P1092 promoter) and to the activation of genome replication. These data suggested that the expression of the
functional E8^E2 protein is used to control viral gene expression and copy number of the HPV11 genome. The
analysis of HPV11 E1 expression plasmids showed that the E6/E7 region, together with the E1 coding region, is
crucial for the production of functionally active E1 protein.
Conclusions: The data presented in this paper suggest that in human osteosarcoma cell line U2OS the gene
expression pattern of the HPV11 truly reflect the expression profile of the replicating HPV genome and therefore
this cellular system is suitable for drug development program targeting HPV replication.
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Papillomaviruses are small double-stranded DNA vi-
ruses that are classified into 16 genera according to
their genotypes [1,2]. The best-studied PVs belong to
the group of alpha-subtype viruses (α-PVs) that infect
the oral and anogenital mucosa of humans and that can* Correspondence: mart.ustav@icosagen.ee
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unless otherwise stated.cause condylomas, genital warts (low-risk α-HPVs, such
as HPV6 and 11) or anogenital cancers (high-risk α-
HPVs, such as HPV16, 18 and 31). The organization of
the HPV genome, which is conserved among PVs,
contains early (E) and late (L) coding regions and a
non-coding long control region (LCR) also known as
the upstream regulatory region (URR). The early region
genes are expressed at different levels throughout the
whole infection period and are responsible for virus
DNA replication (E1 and E2), transcriptional regulational. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and E5). The late genes, which encode the viral capsid
proteins L1 and L2, are expressed in terminally differ-
entiated keratinocytes during the productive phase of
infection. The non-coding upstream regulatory region
contains cis-elements for cellular factors, as well as for
viral DNA replication, transcription and genome main-
tenance. The DNA replication cycle of PVs can be di-
vided into 3 phases: initial genome amplification,
during which the copy number increases rapidly in in-
fected cultures to up to 50-100 copies per cell; the la-
tent replication phase, during which the viral genome is
replicated in synchrony with the cellular DNA; and the
vegetative phase, which includes the second genome
amplification, viral capsid proteins expression and vir-
ion assembly.
Two vaccines against α-papillomaviruses have been
developed and marketed as Cervarix (GlaxoSmithKline,
UK) and Gardasil (Merck Research Laboratories, US).
For review see Malik et al. [3]. These vaccines induce
protective neutralizing antibodies against L1 protein epi-
topes and target the high-risk viruses HPV16 and
HPV18, which are the etiological agents responsible for
the induction of cervical carcinoma. Gardasil also pro-
vides protection against genital warts and cancers of the
anus, vagina and vulva by targeting the low-risk viruses
HPV6B and HPV11. These vaccines are highly effective
in raising specific immune responses and provide pro-
tection against HPV6B, HPV11, HPV16 and HPV18 vi-
ruses when vaccinations are performed in young girls
before sexual exposure [4,5]. The factors preventing the
wide and effective use of the current HPV vaccines in-
clude their cost and their partial protection against many
other papillomavirus types. Although, cross-protection
for closely related HPV types like HPV31 and 45 has
been observed [6] there are at least 13 HPV types which
are potentially oncogenic [7]. Also, current vaccines do
not generate therapeutic effect against pre-existing HPV
infection. Therefore, a real unmet medical need for
drugs with a wider spectrum of specificity against most
papillomaviruses exists.
One of the more specific targets for therapeutic inter-
vention against HPV infection could be the replication
machinery of HPVs. The wide variety of papillomavi-
ruses can be specifically targeted for drug intervention
by focusing on the expression of the viral E1 and E2 pro-
teins and their interaction with cellular proteins and spe-
cific features of the replication machinery. Such drugs
may show wide specificity for HPVs because of the great
similarities in the interactions of the E1 and E2 proteins
of different HPV subtypes with their specific cellular
counterparts and DNA sequences. Thus, drugs devel-
oped against specific HPV replication stages may have a
specific effect on a wide variety of HPVs. To screen forsuch HPV replication inhibitors, a cell-based assay must
be developed in which HPV genome replication can be
effectively quantitated in a high-throughput screening
(HTS) format.
The initial phases of PV infection until the generation
of viral particles can be studied in raft cultures using
transfected PV genomes in human primary keratinocytes
or squamous carcinoma cell lines (e.g., SCC-4) [8]. Al-
ternatively, naturally derived cell lines like W12
(HPV16) or CIN612 (HPV31) already harboring replicat-
ing HPV DNA episomes allow the latent and vegetative
phases of the PV life cycle to be studied [9-11]. Al-
though investigating the molecular mechanisms of HPV
replication in raft cultures is important for a complete
understanding of viral genome replication in differentiat-
ing cells of specific tissues, this method is difficult to use
for screening potential drug candidates in HTS assays.
This issue also applies to the use of primary keratinocyte
cultures for HPV replication because of the need for do-
nors of primary cells, in addition to issues concerning
the genetic uniformity of the assay. Alternatively, NIKS
cells which are non-HPV-containing immortalized kera-
tinocytes could be used to develop an HTS assay, al-
though the robustness of this methodology must be
improved for the effective use of this system [11,12].
Previously, we have successfully employed the human
osteosarcoma U2OS cell line to analyze genome replica-
tion and gene expression in α- and β-HPVs [13-16]. The
initial amplification and latent phases of stable PV repli-
cation can be monitored effectively and the subcloning
of stable HPV cell lines can be performed in this cell
line. Additionally, cloned HPV cell lines can be cultured
under dense conditions, thereby triggering the second
amplification phase in the case of α-HPVs, which is rem-
iniscent of the vegetative amplification that occurs dur-
ing the HPV life cycle before late genes expression [13].
However, virus particle assembly has not been detected
in these cells because sufficient expression of the capsid
proteins L1 and L2 cannot be induced [15,17]. Tran-
scription maps of HPV18 and HPV5 have been compiled
in the U2OS cell line [15,17] and compared with previ-
ous studies [18,19]. This comparison concluded that
transcription maps of these viruses in U2OS cells and in
the keratinocytes in vivo are very similar, if not identical.
Therefore the construction of a high-throughput screen-
ing system for inhibitors of the gene transcription and
genome replication processes of these viruses in U2OS
cells could be possible [15,17,18].
The primary aims of this work were to elucidate the
molecular mechanisms of viral gene expression and gen-
ome replication further and to confirm whether U2OS
cells can be used as a convenient system for molecular
studies of HPV11 and as a platform for screening anti-
viral compounds. We found that the gene expression
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lar to the previously described gene expression in kerati-
nocytes [20-27]. Thus, our data suggest that the HPV11
transcription map obtained herein reflects the situation
in vivo and confirm that a U2OS-based system is poten-
tially suitable for screening anti-HPV11 drugs that sup-
press viral DNA replication.
Results
Replication of HPV11 genomic DNA in the human
osteosarcoma U2OS cell line
The replication initiation of papillomavirus genomes is
primarily determined by the viral replication factors of
E1 and E2, whose levels and effectiveness of action are
modulated by different viral and cellular factors [28,29].
To establish HPV11 replication in U2OS cells, the
HPV11wt genome was transfected into U2OS cells, whichFigure 1 Transient, stable and amplificational replication of the HPV11wt and
as a negative control (A, lane 7, B, lane 23 and C, lane 10). The linearized HPV1
fragments (C, lane 12) was used as size markers, also indicated with arrows. (A
E8- (lanes 4-6) genome. Extrachromosomal DNA was extracted via Hirt lysis at
The replication signal was detected via the Southern blot method with a radi
500 ng of the HPV11wt (lanes 1-11) or HPV11E8- (lanes 12-22) genome, toget
were selected with the antibiotic G418, and at 10 days post-transfection, the c
13-17) or confluent conditions (lanes 7-11 and 18-22). Total DNA was extr
each sample was analyzed as indicated in A. (C) Effect of E8˄E1 and E8˄E2
with 500 ng of the HPV11E8- genome with increasing amounts of either
days post-transfection, and 3 μg of each sample was analyzed as indicated in
signals at different time points at subconfluent and confluent culture conditio
two independent experiments.were then cultivated for up to 6 days, and episomal DNA
was extracted at different time points by Hirt lysis. The
mutant genome HPV11E8- (in which ATG in the E8 ORF
is replaced with ACG at nt 1242 in HPV11 genome) was
included in this assay because our previous studies exam-
ining the HPV5 and HPV18 subtypes in U2OS confirmed
the importance of the E8 ORF-containing the E8^E2 pro-
tein in the regulation of HPV gene expression and genome
replication [15,17]. DNA was purified from the transfected
cells at different time points, treated with DpnI to remove
the input genome, digested with the linearizing endo-
nuclease HindIII and analyzed by Southern blot assay
using a radiolabelled HPV11 genome probe (Figure 1A).
In the first establishment period, the replication of the
HPV11wt genome could be readily detected in U2OS cells
at 3 days post-transfection, with the signal increasing at
later time points (Figure 1A, lanes 1-3). Similar to HPV18HPV11E8- genomes in U2OS cells. The mock-transfected cells were used
1 genome of 100 copies (A, lane 8, B, lane 24 and C, lane 11) and DpnI
) U2OS cells were transfected with 500 ng of the HPV11wt (lanes 1-3) or
3, 4 and 5 days post-transfection, digested with HindIII and with DpnI.
olabelled HPV11 genome probe. (B) U2OS cells were transfected with
her with 2 μg of the linearized pBabe-Neo construct. The transfected cells
ells were split and cultivated under either subconfluent (lanes 2-6 and
acted at the time points indicated at top of the figure, and 3 μg of
proteins on viral genome replication. U2OS cells were transfected
the E8˄E1 or E8˄E2 expression plasmid. Total DNA was extracted at 4
A. (D) The quantitation of HPV11wt and E8- genome DNA replication
ns. The signals were normalized to 10th day time point. Shown is one of
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taining fusion proteins considerably increased the amplifi-
cational replication of the HPV11 genome (Figure 1A,
lanes 4-6).
Next, we focused on the stable replication phase of the
genome when the viral genome replication is constant,
which is necessary for establishing the latent infection
phase, and on the final amplification of the viral ge-
nomes, which can be induced by growing the HPV-
containing U2OS cells under confluent conditions [13].
Thus, the HPV11wt or HPV11E8- genome was co-
transfected into U2OS cells with the linearized pBabe-
Neo plasmid. Then, the transfected cells were cultivated
for up to 1 week under geneticin (G418) selection to elim-
inate untransfected cells. After selection was complete,
the cells were cultivated at lower concentrations of G418
under two different cell culture conditions. Subconfluent
(70-90% confluency) conditions were used to analyze the
latent replication of the viral genome, whereas confluent
conditions (100% confluency) were used to analyze the
final amplification. Total DNA was extracted at the indi-
cated time points, after which the DNA was purified and
linearized with HindIII, and equal amounts of the DNA
samples were analyzed using the Southern blot method, as
described above (Figure 1B). Latent persistence with a
decrease of the HPV11wt genome copy number was
observed during active passaging of the cells under sub-
confluent conditions from day 10 to day 21 (Figure 1B,
lanes 1-6). Although the viral DNA replication level of
the HPV11E8- genome on day 10 was higher than that
of the wt genome at the same time point (Figure 1B,
compare lanes 1 and 12), we observed a similar ten-
dency of decreasing genome copy numbers (Figure 1B,
lanes 13-17). This finding suggests that factors other
than the E8 ORF product containing proteins are in-
volved in the control of HPV11 copy numbers mainten-
ance during the latent phase.
We observed HPV11wt genome persistence when
the cells were cultivated under confluent conditions
(Figure 1B, lanes 7-12, Figure 1D). However, the copy
number increase was significant in the case of the E8-
genome- up to 5-6 times (Figure 1B lanes 18-22,
Figure 1D), providing evidence of the regulatory role of E8
ORF-containing fusion proteins in this phase of replica-
tion. Collectively, the data suggest that U2OS cells are
capable of establishing episomally replicating copies of the
HPV11 genome and that different phases of replication
(latent replication and final amplification) can be modelled
depending on the cultivation conditions.
The HPV11 E8^E2 protein has a negative effect on viral
DNA replication in U2OS cells
E8^E2 transcripts have been identified in many PV sub-
types: BPV1 [30], HPV11 [20,21], HPV16 [31-33], HPV18[18,32], HPV31 [32,34] etc. Previous mapping studies of
HPV5 and HPV18 transcripts in U2OS cells revealed the
following two mRNAs encoding fusion proteins contain-
ing the E8 ORF: E8^E1, which contains the E8 ORF, the
E1 C-terminus and the E2 ORF; and E8^E2, which con-
tains the E8 ORF and the E2 C-terminus. E8^E2 fusion
protein influences viral transcription and genome copy
number control [15,17]. The analysis of viral sequences
and published transcript maps (http://pave.niaid.nih.gov/
#explore/transcript_maps) revealed that the E8^E1 and
E8^E2 proteins could also be expressed by the HPV11
genome. Thus, we engineered expression vectors for the
proteins and determined the effect of their expression on
HPV11E8- genome replication to investigate the effects of
these hypothetical proteins on the regulation of viral
genome replication. The co-transfection of increasing
amounts of either the E8^E1 or E8^E2 expression vec-
tor with the HPV11E8- genome revealed that the ex-
pression of E8^E1 did not affect HPV11E8- genome
replication (Figure 1C, lanes 2-5). However, HPV11E8-
genome replication was suppressed by the E8^E2 pro-
tein in a concentration-dependent manner, suggesting
that HPV11 genome replication can be greatly modu-
lated by this protein (Figure 1C, lanes 6-9). These data
are consistent with previous reports demonstrating that
the HPV11 E8^E2 protein acts as an important negative
regulator of transient DNA replication and gene ex-
pression, as observed in α-papillomaviruses, HPV16
[31,35], HPV18 [13,17] and HPV31 [31,34], as well as
in the β-papillomavirus HPV5 [15].
Mapping of HPV11 polyadenylation cleavage sites (CSs)
Previously, HPV11 gene transcription has been studied
in human clinical samples [20,21,24,27] and in a human
squamous carcinoma cell line [26] employing various de-
tection mechanisms as PCR [21,23,26], cDNA cloning
[27], nuclease mapping [24,25], retrovirus mediated gene
transfer [22,23] and RACE analysis [26]. To compare
viral transcription in U2OS cells with these previous
findings, we decided to map all of the transcripts of the
HPV11 genome generated during its replication in these
cells. Thus, we extracted polyA+ mRNA from U2OS
cells transfected with the HPV11wt or HPV11E8- gen-
ome and analyzed the samples by 3′ RACE, 5′ RACE,
and RT-PCR analyses. The primer sequences used in this
study and their positions in the HPV11 genome are
shown in Figure 2.
The putative HPV11 early polyadenylation CS has
been mapped to the downstream region of the viral E5B
ORF at nt 4384, and the late CS has been mapped to the
downstream region of the L1 ORF at nt 7458 in the
HPV11 genome [20,27]. The HPV11 polyadenylation CSs
used in HPV11-transfected U2OS cells were mapped via
3´ RACE analysis of polyA+ mRNA samples extracted at 4
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transfection. The HPV11-specific primers pr3392 and
pr7188 were used, and the results are shown in Figure 3A
and B, respectively. PolyA+ mRNA from mock-transfected
cells was used as a negative control (Figure 3, lane 4). The
sequencing of the clones revealed that the polyadenylation
CSs previously described for HPV11 genome transcripts
are also used in U2OS cells. We did not observe any
major changes when different phases of replication were
compared; however, the late polyadenylation CS was used
more frequently (Figure 3B).
In addition, we detected three additional CSs at ~3248
(Figure 3A), ~7587 and ~7770 (Figure 3B). These sites
were previously unknown, and their functionality re-
mains unclear.
Mapping of the transcriptional start sites (TSSs) of the
HPV11 transcripts in U2OS cells
The 5´ ends of HPV11 transcripts from transfected U2OS
cells were mapped via 5´ RACE using the HPV11-specific
primers 855c, 1265c and 1558c (Figure 4A-C). Data indi-
cating the HPV11 TSSs in U2OS cells were collected from
the independent sequences of 125 5′ RACE clones. InFigure 2 Schematic map of the HPV11 genome and primers used in RACE a
the open reading frames (ORFs), long control region (LCR), promoters (P90, P2
number before each ORF indicates the first nucleotide of the start codon. The
figure with dashed arrows. The number given with each primer represents its
used for RACE and RT-PCR analysis. The position of each primer in the HPV11general, the results of this analysis clustered the TSSs into
the following 5 distinct promoter regions: P90, P264,
P742, P1092 and P1372.
The pr855c primer was designed specifically to obtain
information regarding the usage of the first three TSSs
in the HPV11wt and E8- genomes. Using this primer,
the analysis revealed that the P90 promoter region was
the most frequently used promoter region in all of the
isolated mRNA samples (Figure 4A).
The pr1265c primer was specifically designed to detect
the TSSs for E8 ORF-containing mRNAs (Figure 4B).
Using this primer for 5′ RACE, we detected the follow-
ing 3 promoter regions: the previously described P90
and P674-714 promoter regions and a potential pro-
moter at P1092, which may be the start site for E8 ORF-
containing mRNAs (Figure 5, species E, J and L). Such
promoter region was also reported in the studies with
HPV16 in human keratinocytes [31]. The transcript
starting at P90 may represent the full-length unspliced
version of the mRNA, which encodes all of the viral
early region proteins, including the viral replication
proteins E1 and E2 (Figures 4B and 5, species A). The
5′ RACE product with the TSS at P674-714 mightnd RT-PCR analysis. (A) Linear depiction of the HPV11 genome, showing
64 and P674-714) and polyadenylation CSs (Cs4384 and Cs7485). The
primers used in transcriptome analysis are indicated at the top of the
5´ end binding position in the HPV11 genome. (B) Sequences of primers
genome and its orientation and sequence are indicated.
Figure 3 Mapping of polyadenylation CSs in the HPV11 genome in
U2OS cells via 3´ RACE. U2OS cells were transfected with the HPV11wt
genome (A and B, lane 1) or together with the linearized pBabe-Neo
construct (A and B, lanes 2 and 3). Mock transfection was used as a
negative control (lane 4). PolyA+ mRNA was extracted at 4 or 10
days post-transfection. All distinct products were purified, cloned,
sequenced and analyzed. (A) 3´ RACE analysis of the HPV11 early
region CSs using the HPV11-specific primer pr3392. The indicated
3´ RACE products represent the potential CSs at nt 4384 and nt ~3248.
(B) 3´ RACE analysis of the HPV11 late region CSs using the HPV11-
specific primer pr7188. The indicated 3´ RACE products represent the
potential late CSs at nt 7485, at nt ~7770 and at nt ~7587.
Figure 4 Mapping of HPV11 TSSs and splice junctions in U2OS cells
via 5′ RACE. U2OS cells were transfected as follows: 500 ng of the
HPV11wt genome (lane 1), 500 ng of the HPV11wt genome together
with 2 μg of the linearized pBabe-Neo construct (lanes 2 and 3), 500
ng of the HPV11E8- genome (lane 4), or mock transfection (lane 5).
PolyA+ mRNA was extracted at 4 and 10 days post-transfection, and 5′
RACE analysis was performed using the HPV11-specific primers pr855c
(A), pr1265c (B), pr1558c (C), pr2891c (D) and pr3692c (E). RT-PCR
analysis was performed using the HPV11-specific primers pr1241
and pr3692c (F). All distinct PCR products (marked with letters from A
to Q; the same designations are used in the map represented in
Figure 5) were cloned and sequenced for the analysis of TSSs and/
or splice junctions.
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which lacks the E6 and E7 ORFs; however, we cannot
exclude the possibility of a splicing event at the splice
donor site at nt 1459.
The pr1558c primer was designed to specifically detect
only the 5′ end of the full-length (unspliced) mRNA.
The analysis revealed that the full-length mRNA starts
at P90 (Figure 4C). However, we were not able to detect
the mRNA with a TSS at P674-714, indicating that tran-
scripts from P674-714 are spliced at nt 1459.
We also detected a putative promoter region at P1372
that has not been previously described as a promoter re-
gion (Figure 4D and E). The presence of the promoterregion at nt 1374 was suggested by Renaud et al. [26];
however, no additional data were provided. The mRNAs
starting at promoter region P1372 potentially encode the
Figure 5 HPV11 transcription map obtained in transiently transfected U2OS cells. The HPV11 ORFs, LCR, promoters (P90, P264, P674-714, P1092, and
P1372) and polyadenylation CSs (Cs 4384 and Cs 7485) are shown at the top of the figure. All of the HPV11 transcripts from transiently transfected
U2OS cells (indicated with letters from A-Q, shown at left) are presented, showing the exons (solid boxes), introns (lines) and splicing donor
and acceptor sites (nt numbers in HPV11 genome). The inferred 5′ ends of the RT-PCR products (N-Q) are indicated with dashed boxes. The
coding potential is described to the right of each transcript, and references are provided when similar transcripts were found by others,
namely, Chiang et al. [23], Chow et al. [20], and Renaud et al. [26].
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sociated splicing events (Figure 5, species F, K, and M).
Thus, in U2OS cells, we detected viral transcription
from promoters that have also been described in clinical
samples. This result strongly support that U2OS cells
provide an adequate environment for HPV11 genome
replication and gene expression.
In addition, we compared the transcripts obtained dur-
ing the transient, latent and final amplification phase of
replication. We did not observe any major changes in the
mRNA pattern. However, regulation of the levels of the
mRNA encoding viral replication helicase E1 (Figure 4C,
species A, compare lanes 1 and 3) could be detected,
which suggests that a second genome amplification occurs
due to the intensive transcription of mRNAs encoding the
replication proteins.
We also conducted 5′ RACE assays for the HPV11E8-
genome to detect differences in transcriptional activity. The
most significant differences were detected for transcripts
encoding the E1 protein, which were weakly detectable in
the HPV11wt genome on day 4 and which were slightly
enhanced in the HPV11E8- mutant genome (Figure 4C,
compare lanes 1 and 4). RT-PCR analysis with the
E8-specific primers pr1241 and pr3962c showed that pro-
teins containing the E8 region negatively regulated their
own mRNA transcription (Figure 4F, compare lanes 4 and 1).
Mapping of HPV11 splice junctions in viral early
transcripts
The splice junctions of the HPV11 transcripts found in
the polyA+ mRNA extracts of transfected U2OS cells were
mapped via either 5′ RACE with the HPV11-specific
primers pr2891c and pr3692c (Figure 4D and E) or RT-
PCR with the primers pr1241 and pr3692c (Figure 4F). In
total, 313 mRNA transcripts were cloned, sequenced and
analyzed. The splice junction analysis enabled us to iden-
tify transcripts that contain splice junctions, embracing all
possible combinations of the splice donors at nt 847, nt
1272 and nt 1459 with the splice acceptors at nt 2622, nt
3325 and nt 3377.
The primer pr2891c was designed to detect the 5′
ends of the mRNAs with the splice acceptor site at nt
2622 (Figure 4D). The analysis revealed 4 products,
which were designated with letters G, H, I and K. Tran-
scripts G, H and I all exhibited the same splice donor
site at nt 847 but different TSSs (P90, P264 and P674-
714, respectively). Transcript K was spliced at 1459/
2622, and its mRNA started at P1372. All of the prod-
ucts potentially encode the viral E2 protein, product G
encodes both the viral E6 and E7 oncoproteins, whereas
product H only encodes one oncoprotein, E7 (Figure 5,
species G, H, I, K).
The primer pr3692c, which is after the third splice ac-
ceptor site at nt 3377, was designed to detect the 5′ endsof mRNAs with the splice acceptor site at nt 3325 or nt
3377 (Figure 4E). Five RACE products were detected
when 5′ RACE analysis was conducted with this primer.
Three of these products were spliced at 847/3325 (B, C,
and D), one at 1459/3325 (F) and one at 1459/3377 (M).
The TSSs of these products varied, including P90 (B),
P264 (C), P674-714 (D) and P1372 (F and M). Depend-
ing on the TSS, the products encode the viral E6 (B and
C) and E7 (B) oncoproteins and the E1^E4 (B, C, and D)
protein. The most frequently occurred mRNA of these 5
transcripts was species F.
The RT-PCR analysis with pr1241 and pr3692c was de-
signed to detect a rarely used splice donor site at nt 1241.
The analysis detected the following 3 rare splicing combi-
nations: 1241/2622, 1241/3325 and 1241/3377 (Figure 4F).
The 5′ ends of these species remain unknown; however,
some of the mRNAs may be transcribed from the above-
described TSS at P1092 and encode the viral E8^E2,
E8^E1 and E4C proteins (Figure 5, species E, J and L, re-
spectively). However, according to previous studies, their
TSS may be at the late promoter region P674-714 [23]. If
the same TSS is used in the transiently transfected U2OS
cell system, then the transcripts encode several truncated
forms of E1: E1M, E1MˆE2C and E1MaˆE4 (Figure 5, spe-
cies N, O, P and Q).
All of the transcripts included in the present study
may potentially encode the viral E4 (except for tran-
scripts with an acceptor site at nt 3377), E5a and E5b
proteins, at the end of the viral early region (Figure 5).
The results of 5′ RACE analysis using the HPV11-
specific primers pr5747c and pr7260c to detect late viral
gene products splicing and TSSs included mixed, pri-
marily double-spliced products (data not shown). None
of these products were intact to encode the viral struc-
tural proteins L1 and L2, indicating that full-length late
mRNAs are not expressed and, thus, that viral particles
cannot be formed.
The importance of leader sequences carrying the E6 and
E7 ORFs for HPV11 E1 protein expression
HPV E1 protein expression can be regulated by pro-
moter activity, pre-mRNA splicing, mRNA stability, the
unusual polycistronic mRNA translation mechanism,
nuclear export and import and E1 protein stability. All
of these aspects are crucial for effective HPV genome
replication during the viral life cycle. In the present
study, we focused on identifying the important elements
for the transcription of E1 ORF-containing stable mRNAs
and then on using this information to achieve functional
E1 protein expression. Chow et al. reported that the E1
protein mRNA transcription start site is at the late pro-
moter in the E7 ORF (P674-714) and that the mRNA
whose TSS is at nt 90 is believed to either encode the viral
E6 protein or be an unprocessed primary transcript of the
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U2OS system revealed that the only mRNA that can en-
code the E1 protein starts from the early promoter region
P90. We have previously demonstrated that the HPV18
E1 protein is translated from spliced polycistronic mRNA,
which carries partial spliced sequences of the E6 (generat-
ing E6* protein) and E7 ORFs [36,37]. In the present
study, we further evaluated the role of the E6/E7-contain-
ing leader sequences for HPV11 E1 expression. We de-
signed four different HPV11 E1 expression plasmids. First,
we designed an E6/E7 ORF-containing E1 expression plas-
mid (Leader+, or L+) in which the E6 and E7 translation
initiation codons were modified via a single-nucleotide
ATG→ACC mutation in both genes. Second, we de-
signed an E1 expression vector lacking the leader se-
quence of the E6/E7 region (Leader-, or L-) in which the
CMV promoter should function as the late viral promoter
P674-714, directly in front of the E1 ORF. In designing
the third and the fourth E1 expression vectors, we consid-
ered the available information for the high-risk viruses
HPV16 [38], HPV18 [17,18,36] and HPV31 [39], in which
the E6 ORF contains an intron within its sequence. How-
ever, a similar intron has not been described in theFigure 6 HPV11 E1 expression from E1 plasmids and transient replication of th
of the HA-epitope tagged HPV11 E1 protein from transiently transfected
HPV11 E1 expression plasmids (indicated at the top of the figure). Wester
HPV11 E1 protein (A) and the cellular marker α-tubulin (B). (C) The HPV1
HPV11 URR plasmid in transiently transfected U2OS cells. U2OS cells were
and 1-5000 ng of different E1 expression plasmids. Extrachromosomal DN
of each sample was analyzed as indicated in Figure 1A. The replication si
Mock-transfected U2OS cells were used as a negative control (lane 27), an
a size marker. The linear HPV11 URR and DpnI fragments are indicated wHPV11 genome. We were interested in determining
whether the presence of an intron between the CMV pro-
moter and the E1 region could have any influence on
HPV11 E1 protein expression levels. Therefore, we de-
signed E1 expression vectors with a heterologous artificial
intron originating from the pRL-TK vector (Promega),
which was approximately the same size as the HPV16 E6
intron. We inserted this intron into the E1 (L-) expression
vector between the CMV-promoter and the E1 ORF in
one or two copies: a single intron-containing vector, desig-
nated Int1, and a vector with two introns, designated Int2.
The E1 proteins were tagged with an HA-tag for the
evaluation of E1 protein expression levels as described
previously [36,37].
To test the efficiency of E1 expression from the de-
signed vectors and to identify the effect of the expressed
E1 protein on origin-containing plasmids, 100 ng of the
HPV11URR plasmid was co-transfected with 100 ng of
HPV11E2 and with various amounts of HPV11E1 ex-
pression plasmids (10, 100, 1000, or 5000 ng) into U2OS
cells. E1 protein expression was evaluated via Western
blotting using an HA-tag-specific antibody (Figure 6A).
Such tagging of the E1 protein did not interfere with thee URR-plasmid in the presence of the E1 and E2 proteins. (A, B) Detection
U2OS cells. The cells were transfected with 1-5000 ng of different
n blot analysis was performed at the 24 h time point to detect the
1 E1 and E2 proteins initiated DNA replication from the episomal
co-transfected with 100 ng of the HPV11 URR plasmid, 100 ng of E2
A was extracted at 24 and 48 h post-transfection via Hirt lysis, and ½
gnal was detected with a radiolabelled HPV11 URR specific probe.
d 200 pg of the linearized HPV11 URR plasmid (lane 28) was used as
ith arrows.
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(data not shown) and enabled us to evaluate E1 protein
expression levels. E1 expression levels varied greatly de-
pending on which of the E1 plasmids was used. The E1
protein expressed from the L+ plasmid could be de-
tected when as little as 10 ng of the expression plasmid
was transfected (Figure 6A, lane 1), whereas the L- plas-
mid E1 protein signal was detectable when at least a
100-times higher concentration was used (Figure 6A,
lane 5). The plasmid containing one intron expressed E1
at the same level as the L+ plasmid (Figure 6A, compare
lanes 1-3 and 7-9), indicating that the natural leader se-
quence of HPV11 can be substituted with the heterol-
ogous intron. The data suggested that sequences
preceding the E1 ORF in polycistronic mRNA play an im-
portant role in determining E1 protein expression. The
construct with a double intron had an even stronger ef-
fect, providing an extremely high level of E1 protein ex-
pression (Figure 6A, lanes 10-13).
We also measured the functional activity of the
expressed E1 protein in transient replication assays. The
DpnI-resistant extrachromosomal DNA replication sig-
nals of HPV11URR were analyzed by Southern blotting
with an HPV11URR-specific radiolabelled probe. At a
constant E2 level, the effects of different E1 expression
levels from the various E1 expression plasmids were also
reflected in the Southern blot replication assay, where
E1 protein expressed from the L+ and L- plasmids sup-
ported URR-containing plasmid replication according to
the observed E1 expression levels (Figure 6C, lanes 1-
12). E1 from the plasmid containing one intron restored
the effect of the L+ system (compare lanes 13-18 and
lanes 1-6), and E1 from the plasmid containing two in-
trons supported DNA replication most efficiently. The
replication signal was detectable when a concentration
as low as 1 ng was used (lanes 19 and 20), and clear tox-
icity was observed in cells at concentration of 1000 ng
(lanes 25 and 26).
Mapping of HPV11 E1 mRNA 5′ ends transcribed from
various E1 expression vectors
All of the previously described HPV11 promoters have
been mapped to the E6/E7 protein coding region at nt
90, nt 264 and nt 674-714. In our L+ E1 expression sys-
tem, the first viral promoter P90 is disrupted, and the E6
ORF starts at nt 105, whereas the remaining promoters
and potential splice donor sites at leader sequence are
intact in the E6/E7 ORF region. The CMV promoter is
an extremely strong promoter; however, viral promoters
may also function and initiate transcription on their own
or splicing may still contribute to the generation of
translatable E1 mRNA. Therefore, we searched for evi-
dence of functional viral promoters in the L+ E1 expres-
sion vector or for evidence of a splicing event occurringin the E6/E7 ORF, as in the case of the high-risk HPVs.
One microgram of different E1 expression vectors was
transfected into U2OS cells, and polyA+ mRNA was ex-
tracted at 24 h post-transfection. A 5′ RACE analysis
was performed with the HPV11-specific primer
pr1265c. All of the observed 5′ RACE products shown
in Figure 7A were gel purified, cloned and sequenced,
and the results are shown in Figure 7B. As expected,
strong signals could be detected from transcripts start-
ing from the CMV promoter region. The E1 transcript
from the L+ expression vector was unspliced, and the
CMV promoter mimicked the early promoter at P90
(Figure 7A and B, species a). The L- mRNA was also
unspliced, and the CMV promoter served as the late
promoter at P674-714 (Figure 7A and B, species c). The
insertion of the intron between the CMV promoter and
the E1 coding region (Int1) showed that the intron was
spliced out in all of the sequenced clones (Figure 7A
and B, species d). The E1 expression vector Int2, which
contained two introns between the CMV promoter and
the E1 coding region, provided the following double-
spliced products: a) both of the introns were spliced
out or b) a single intron was spliced, leaving the first
intron intact (75% of clones) (Figure 7A and B, species
e). A weak signal could be detected for the L+ sample
at the level of the 750 bp size marker (Figure 7A and B,
species b). The analysis of this product showed that the
viral promoters were functional in the presence of the
CMV promoter (Figure 7A and B, species b) because
we were able to detect the following two transcripts:
one starting at P264 and the other at the P674-714 pro-
moter region. However, we did not detect any splicing
event occurring in the E6/E7 region.
We conclude that the E1 plasmids with introns be-
tween the CMV promoter and the E1 gene restored E1
expression and the functionality of E1 as a replication
helicase. Therefore, different α-HPVs use different
strategies for the production of the E1 replication fac-
tor. Thus, high-risk viruses generate E1-encoding
mRNA via splicing, whereas low-risk viruses use their
full leader sequence for expressing a biologically active
E1 protein.
Discussion
Previously, we have used the human osteosarcoma cell
line U2OS to study α- and β-HPV DNA replication and
gene expression patterns [13-17]. Our analyses employ-
ing the HPV11wt and E8- genomes in U2OS cells
showed that the events of the papillomavirus three-step
replication cycle could be mimicked, as in native kera-
tinocyte cell lines, including the first amplification of the
virus genome; the latent phase, where the genome copy
number is stable; and the second genome amplification
phase. The initiation of the replication of the HPV11wt
Figure 7 Mapping of HPV11 promoter activity from E6/E7-containing E1 expression plasmids. (A) U2OS cells were transfected with 1 μg of different
HPV11 expression plasmids (indicated at top of panel A and schematically introduced in panel B). PolyA+ mRNA was extracted at 24 h post-transfection,
and 5′ RACE analysis was performed with the HPV11-specific primer pr1265c. The products from a-e were sequenced, and their structures are shown in
panel B. Mock-transfected U2OS cells were used as a negative control (lane 5). (B) Schematic map of the 5′ RACE products from the E1 expression
plasmids, together with HPV11 E1 L+, L-, Int1 and Int2 expression vector maps. All of the E1 protein-coding transcripts (indicated with letters from a-e,
shown at left) are shown, indicating their exons (solid boxes), introns (lines) and potential TSSs in E6 and E7 ORFs (nt numbers).
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in U2OS cells. Some differences in maintenance were
observed when HPV11-positive cells were grown as ac-
tively proliferating cultures versus slow dividing dense cul-
tures; intensive passaging of the cells led to some
reduction of the viral genome copies for both, the
HPV11wt and E8- genomes. The same tendency was also
observed for the subconfluently cultivated low-risk
HPV11 and HPV6b subclones when we introduced re-
ligated HPV genomes into U2OS cells [13]. The high-risk
HPV18 and HPV16 maintain stably their genomes in the
cells under subconfluent conditions with active passaging
[13]. Subclones of the β-papillomavirus HPV5 and HPV8
also maintain their copy numbers under subconfluent
conditions [13,15]. In contrast, under confluent culture
conditions, the HPV11wt genomes are effectively main-
tained in the U2OS cells, while in the case of HPV11E8-mutant 5 to 6 times amplification of the genome occurred.
These data indicate that the amplification of the HPV11
E8- mutant genomes under confluent culture conditions
generally exhibits the features of α-HPV replication, as
previously described for the α-papillomaviruses HPV18
and HPV16 [13,17]. Notably, the β-papillomavirus HPV5
is not capable of amplifying the replication signal in con-
fluent cultures of U2OS cells [15]. One of the reasons may
be the difference in the structural organization of the URR
regions and regulation of gene expression between the α-
and β-papillomaviruses or the response to certain positive
cellular factors capable of activating viral replication,
which are expressed at considerably higher levels com-
pared with those of subconfluent cultures. Alternatively,
cell division in confluent cultures is slowed down, which
allows the viral genome to replicate for a longer period be-
cause HPV genomes are not restricted to once-per-cell
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in S phase but also in G2 phase [11,14,40].
The transcriptional data obtained from the transiently
transfected HPV11-positive U2OS cell line are identical
to the transcripts found in condylomata acuminata [20],
experimental condylomata [23] and the human squa-
mous carcinoma cell line SCC-4 [26]. Indications of
transcription events from late region genes could be ob-
served from both promoter analyses and the mapping of
the polyA signal. However, the isolation of intact
mRNAs from the L1 and L2 genes was unsuccessful, in-
dicating that these transcripts are not stable and that the
L1 and L2 structural proteins are not expressed in U2OS
cells. Although the second amplification of the viral gen-
ome could be observed, the expression of the late pro-
tein mRNA was not detected.
The E8 ORF is highly conserved among α-HPVs. Dur-
ing HPV11 transcripts analyses, we identified two
mRNAs with an E8 ORF within their sequences: one
possibly encoding the E8^E1 fusion protein and a sec-
ond possibly encoding the E8^E2 fusion protein. The fu-
sion protein E8^E2 is responsible for the repression of
viral protein expression, including that of the viral repli-
cation proteins E1 and E2 [15,17,31,34]. Mutation of the
E8 start codon in the HPV11 genome increase DNA
replication by at least 6-fold. However, in the case of the
HPV5, HPV18 and HPV31, the effect on DNA replica-
tion initiation is even greater, ranging from 30- to over
100-fold [15,17,34]. Analyzing the expression of the
E8^E1 and E8^E2 fusion proteins and their effect on
HPV11E8- genome replication in the present study re-
vealed that the E8^E1 protein did not affect DNA replica-
tion and may be important in other aspects of the HPV11
life cycle. In contrast, the E8^E2 protein repressed gen-
ome replication in a concentration-dependent manner.
Analyzing the HPV11E8- genome mRNA transcripts re-
vealed that the E8^E2 protein negatively regulates its own
mRNA transcription, in addition to repressing the tran-
scription of E1 and E2 mRNAs, suggesting that this pro-
tein is part of the negative regulatory loop for the viral
gene expression.
Analysis of the transcripts obtained from HPV11-
positive U2OS cells indicated that the only transcript en-
coding the E1 replication protein is the polycistronic
mRNA consisting of all of the early genes in the HPV11
genome: E6, E7, E1, E2, E4, E5a and E5b. Previous stud-
ies of HPV11 transcripts and E1 protein expression have
suggested that E1 can also be translated from mRNA in
which the TSS is at the end of the E7 ORF; therefore,
the E6 and E7 genes are absent [20]. To study this differ-
ence, we designed two E1 expression vectors: one con-
taining the E6 and E7 leader sequence and a second in
which the leader sequence was absent. The E1 protein
from the L+ plasmid was functional and supported DNAreplication, whereas the E1 protein from the L- plasmid
was not expressed and did not support viral DNA repli-
cation as effectively as that from the L+ plasmid. This
difference might be explained by mRNA stability or by
translational effectiveness. In the case of high-risk α-
HPVs (e.g., HPV16, HPV18, and HPV31), an intron
within the E6 ORF that is spliced in E1-containing
mRNAs, which might be the key event in the expression
of biologically active E1 protein [17,36,38,39]. To study
this possibility in the HPV11 system, we generated E1
expression vectors in which the leader sequence was
substituted with one or two heterologous artificial in-
trons. The splicing event between the promoter and E1
gene restored the effect of the leader sequence. The E1
protein was expressed effectively and supported viral
DNA replication. Two introns have an even greater ef-
fect on E1 protein expression and activity. In contrast,
the analysis of the transcripts obtained from the L+ se-
quence did not reveal any introns within the leader se-
quence, indicating that other regulatory factors in the
HPV11 E6/E7 region assure effective and biologically ac-
tive E1 protein expression.
Conclusions
The analysis of HPV11 replication and mapping of the
mRNA transcripts indicated that U2OS cells provide an
adequate environment for HPV11 replication and gene
expression. Considering the immortalized state and ease
of cultivation of this cell line, this system could be a
valuable tool for papillomavirus molecular biology-
related studies, as well as for the development of high-
throughput analyses for the screening and validation of
anti-HPV drugs.
Materials and methods
Cell lines and transfection
U2OS cells obtained from the American Type Culture
Collection (ATCC) (number HTB-96) were grown in
Iscove’s modified Dulbecco’s medium (IMDM) supple-
mented with 10% fetal calf serum (FCS). The cells were
transfected via electroporation (220 V, 975 μF) using a
Bio-Rad Gene Pulser II apparatus supplied with a capaci-
tance extender (Bio-Rad Laboratories). Episomal HPV11
genome amplification was achieved by growing trans-
fected cells under confluent conditions for 10 days with-
out passaging. At 48 h post-transfection, the cells were
subjected to geneticin sulfate G418 selection (final con-
centration, 400 μg/ml, BioTop) to eliminate untransfected
cells. The medium was changed every second day. Total
DNA was extracted at the time points indicated below.
Plasmids
The HPV11 genome sequence and its numbering are
based on the sequence of GenBank accession no. M14119.
Isok-Paas et al. Virology Journal  (2015) 12:59 Page 13 of 15Minicircle producing plasmid backbone pMC.BESBX [41]
was inserted into BamHI site in the HPV11 genome L1
region (between nt 7072 and 7073 in HPV11 genome). Al-
most all of bacterial backbone is removed during minicircle
plasmid preparation [14]. The final product is circular
HPV11 genome DNA with 91 bacterial backbone derived
nucleotides between positions 7072 and 7073. For the
HPV11E8- mutant genome, the ATG start codon from
pMC.BESPXHPV11wt (at the nt 1242 position in HPV11
genome) was mutated to ACG. To produce HPV11 gen-
ome for electroporation: HPV11wt and HPV11E8- mini-
circle genomes were produced from the parental plasmids
in E. coli and purified as described by Reinson et al. [14].
To achieve complete removal of the unrecombined paren-
tal plasmids and the pMC.BESPX vector, the plasmids
extracted from the bacterial cells were subjected to an
additional gel purification step.
The E8^E1 expression vector pQMCFH11E8E1 was
generated by amplification of the HPV11 E1 C-terminus
from the plasmid pMC.BESPXHPV11wt with the primers
11E8-E1_F_NheI (5′-TCTGCTAGCGCCACCATGGCTA
TTCTGAAGTGGAAGCTGCAACGCAGAAATGGGAA
TGCAGTATATGAACTATC-3′) and 11E1_R_Bsp (5′-
CCCTTCGAATCATAAAGTTCTAACAACTGATCCT
G-3′). The E8^E2 expression vector pQMCFH11E8E2
was generated by amplification of the HPV11 E2 C-
terminus from the pMC.BESPXHPV11wt plasmid with




ACATAAACCC-3′). The PCR products were cleaved
with the enzymes NheI and Bsp119I (Thermo Scien-
tific) and inserted into the vector pQMCF_MCS_9
(Icosagen Cell Factory Ltd.), which was opened
through NheI/Bsp119I digestion.
The cloning of the HPV11 URR plasmid and the L+
E1 and E2 expression vectors was described previously
by Kadaja et al. (designated pUCURR-11, pMHE1-11
and pQMNE2-11, respectively) [37]. The HPV11 L- E1
expression vector was obtained by amplification of the
E1 ORF from the HPV11 L+ E1 expression vector (nt
823 to 2781 in the HPV11 genome) using the primers
E1.Xba-11 (5′-CCTCTAGATCCATGGCGGACGATTC
A-3′) and E1.3.11 (5′-GGAAGCTTTTCTTCATAAAGT
TCTAACAACTGATCC-3′). The PCR product was
cleaved with XbaI and HindIII and inserted into the XbaI/
HindIII site of the eukaryotic expression vector pQM-
Ntag/Ai + (Icosagen Cell Factory Ltd.). The HPV11 Int1
and Int2 E1 expression vectors were obtained by cleaving
the vector pRL-TK (Promega) with the enzymes HindIII
and NheI and by cloning the pRL-TK intron-containing
region into the XbaI site of the HPV11 L- vector. By
blunt-end cloning, we obtained E1 expression plasmidswith one (Int1) or two (Int2) introns between the CMV
promoter and the E1 gene. All of the modifications of the
HPV11 L+ E1 expression vector described in Kadaja et al.
were also performed for the L-, Int1 and Int2 E1 expres-
sion plasmids [37].
RNA extraction and rapid amplification of cDNA ends
(RACE)
U2OS cells were transfected with 500 ng of the
HPV11wt or HPV11E8- genome, and samples used for
establish the stable expression were transfected with 2
μg of the linearized pBabe-Neo construct. PolyA+ RNA
templates were extracted from cells using a Micro-
FastTrack™ 2.0 Kit (Invitrogen) at 4 and 10 days post-
transfection. Then, 275 ng or 350 ng of polyA+ RNA
was used as a template for 5′ or 3′ RACE analysis, re-
spectively. Both the 5′ and 3’ RACE assays were per-
formed using a SMARTer™ RACE cDNA Amplification
Kit (Clontech) according to the manufacturer’s instruc-
tions. The positions and the sequences of the HPV11-
specific primers used for the amplification of the RACE
products are shown in Figure 2. The amplified RACE
products were purified from agarose gels, cloned and
fully sequenced as single clones.
RT-PCR
Samples of 200 ng of polyA+ RNA extracted from cells
using a Micro-FastTrack™ 2.0 kit (Invitrogen) were sub-
jected to DNase treatment with a Turbo DNA-free Kit
(Ambion), and cDNA was synthesized using a Super-
script III First Strand cDNA synthesis Kit (Invitrogen)
according to the manufacturer’s instructions. Then, 4 μl
of cDNA was used in a single PCR reaction, along with
4 μl of 5× HOT FIREPol® Blend Master Mix with BSA,
12.5 mM MgCl2 (Solis Biodyne) and the HPV11-specific
primers pr1241 and pr3692c (Figure 2) in a 20 μl of total
reaction volume. Amplification of the newly synthesized
cDNA was performed using the following program: 95°C
15′, 94°C 30″, 65°C 30″, and 72°C 2′, for a maximum of
25 cycles. The RT-PCR products were purified from
agarose gels, cloned and fully sequenced as single clones.
Replication analysis
Extrachromosomal DNA was extracted from the trans-
fected cells at 1 to 5 days post-transfection via the modi-
fied Hirt method [42], or total genomic DNA was
extracted at 10 to 21 days post-transfection from U2OS
cells as described previously [13]. Before Southern blot
analysis, half of each extrachromosomal DNA sample or
3 μg of each total DNA sample was treated with the lin-
earizing enzyme HindIII, and non-replicated, bacterially
produced dam-methylated input DNA was fragmented
with DpnI (Thermo Scientific). The DNA samples were
resolved on a 0.8% (extrachromosomal DNA) or 0.6%
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EDTA (TAE) buffer. Electrophoresis was performed at
0.8 V/cm for 20 h. The separated DNA fragments were
treated with 0.1 M hydrochloric acid, denatured with Sol
A (0.5 M NaOH, 1.5 M NaCl), neutralized with Sol B (1
M Tris pH 7.4, 1.5 M NaCl), transferred to a Hybond-N+
membrane (Amersham Pharmacia Biotech) via the South-
ern blot method and hybridized with a radiolabelled
HPV11-specific probe. HPV11 replication signals were de-
tected via exposure to X-ray film.
Western blotting
Cells in a 60 mm culture dish were washed twice with 1×
PBS, detached from plates with PBS-3 mM EDTA (pH
7.5) and collected via centrifugation. The cells were lysed
with 1× Laemmli buffer (4% SDS, 20% glycerol, 120 mM
Tris-Cl (pH 6.8), and 200 mM DTT), boiled at 100°C for 5
min and centrifuged for 10 min at 14000×g. The proteins
were separated in 8 to 10% polyacrylamide-SDS gels and
transferred to Immobilon-P membranes (Millipore, USA).
The HPV11 E1 protein with a hemagglutinin (HA) epi-
tope tag was detected using the rat polyclonal antibody
3F10-HRP (12013819001; Roche), which was diluted
1:500. An antibody against the cellular marker α-tubulin
(B-512, Sigma-Aldrich) was used at a dilution of 1:5000.
For visualization, a secondary α-mouse-HRP antibody
(LabAS) was used at a dilution of 1:10000.
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